Furthermore, Venetoclax, another BCL-2 inhibitor, has recently been approved for the treatment of AML as a single agent18 and trials are on-going investigating combinations with either FLT3 inhibitors or demethylating agents, to test its efficacy in the treatment of AML39,40. Here, FLT3 is linked to acute myeloid leukemia.